An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

BPS804

IV administration of BPS804 in 5% Dextrose solution

Trial Locations (2)

77030

Mereo Investigator Site, Houston

87106

Mereo Investigator Site, Albuquerque

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mereo BioPharma

INDUSTRY

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY